The global cluster headache syndrome market size is expected to be US$ 948.9 million in 2023. The growing prevalence of neurological and lifestyle-related disorders, external funding for Research and Development, and demand for minimally invasive surgeries are other factors that drive the market growth. The overall demand for cluster headache syndrome treatment is projected to grow at a CAGR of 5.2% between 2023 and 2033, totaling around 1,578.8 million by 2033.
Cluster headache, a neurological disorder, is characterized by severe headaches recurring on one side of the head, usually around the eye. Cluster headache is often accompanied by autonomic symptoms such as excessive tears, swelling of the eye, and nasal decongestion.
In cluster headache syndrome, individuals often suffer from excruciating attacks of unilateral headaches. Some symptoms like migraine, such as sensitivity to light and sound and nausea may also occur with a cluster headache. The causes of cluster headaches are unknown, though some rare causes may be hereditary, smoking, and hypothalamus dysfunction.
| Data Points | Key Statistics |
|---|---|
| Cluster Headache Syndrome Market Value 2023 | US$ 948.9 million |
| Cluster Headache Syndrome Market Projected Value (2033) | US$ 1,578.8 million |
| Cluster Headache Syndrome Market CAGR (2023 to 2033) | 5.2% |
The intense pain is known to be caused by the dilation of blood vessels, creating pressure on the trigeminal nerve. Diagnosis of cluster headache syndrome can often be misleading, mismanaged, and misdiagnosed. The cluster headache attacks often occur multiple times daily, each lasting not more than three hours without treatment.
The attacks occur daily for several weeks or months and then diminish for a period, though they can last for months or even years in some people. The prevalence of cluster headache syndrome in men is three to four times more than in women. Episodic and chronic are the two types of cluster headaches.
Unlike chronic cluster headaches, the episodic type is characterized by relatively long and pain-free remissions between headaches. About 10 percent of people suffering from cluster headaches have the chronic syndrome. A physical examination of pupils may help doctors detect signs of a cluster headache. For instance, one of the pupils may appear smaller than the other or sag in the eyelid.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for cluster headache syndrome treatment is projected to increase at a CAGR of 5.2% during the forecast period between 2023 and 2033, reaching a total of US$ 1,578.8 million in 2033, according to a report from Future Market Insights (FMI). From 2017 to 2022, sales witnessed significant growth, registering a CAGR of 4.5%.
In recent years, there has been a spike in chronic migraines and cluster headache syndrome prevalence. As per WHO’s report, globally, it has been estimated that the prevalence among adults of current headache disorder (symptomatic at least once within the last year) is about 50%. Half to three-quarters of adults aged 18 to 65 years in the world have had headaches in the last year, and among those individuals, 30% or more have reported migraine.
However, the growing investments in research programs to develop effective drugs for treating migraines have boosted the market growth of cluster headache syndrome. During the historic outlook, the market is projected to experience moderate growth, backed by rising awareness and increasing healthcare spending in major regions like North America & Europe.
The increasing prevalence of cluster headache patients with a positive family history enhances the scope of treatment
Although cluster headache is a relatively uncommon primary headache disorder, with a lifetime prevalence of 124 per 100,000 persons, with an annual prevalence rate of 53 per million, it is still a cause for concern across major regions. This is majorly attributed to the prevalence of sedentary lifestyles, which in large part is associated with stressful work environments and extensive durations spent on consumer electronic gadgets. Also, increased television viewing and computer usage have contributed to the growth of cluster headache syndrome.
The rising pervasiveness of cluster headache patients with a positive family history is further anticipated to necessitate the need for treatment for cluster headache syndrome. For instance, according to a research article published by BMC in April 2020, a systematic review and meta-analysis were carried out by the guidelines for preferred reporting items for systematic reviews and meta-analysis protocols (PRISMA- P). It was found that an estimated prevalence of CH patients with a family history was around 6.27%, with an overall I2 of 73%.
While there is no known cure for cluster headaches, doctors and clinicians have prescribed various drug-based and therapeutic treatment approaches to mitigate the incidence of this disorder. Besides, approaches such as administering pure oxygen and triptans have proven highly effective in managing cluster headache syndrome. Furthermore, researchers are studying several potential treatments, including occipital nerve stimulation and deep brain stimulation. These involve implanting electrodes in the brain to send impulses to the occipital nerve and inhibit pain signals.
The absence of Healthcare Experts May Hamper the Market Growth
A shortage of knowledge among healthcare providers, poor public awareness, and government measures to lessen healthcare expenditure are the major barriers to effective care in the cluster headache syndrome market.
Principal Consultant
Exceptional Healthcare Infrastructure & Availability of Specialists in the Region to Propel Market Growth
In terms of geographic divisions, North America is expected to hold the largest share, accounting for 41.2% share in the cluster headache syndrome market in 2023. According to Future Market Insights analysis, the region is projected to maintain its governance over the projection period, backed by flourishing advanced healthcare infrastructure along with the advent of advanced technologies to diagnose the syndrome and the increasing prevalence of migraines.
The increasing approval of novel treatment options for cluster headaches by regulatory authorities, such as the USA Food and Drug Administration (FDA), is driving the growth of the global cluster headache market. For instance, according to the USA FDA News Release, released in June 2019, the USA FDA approved the Emgality (galcanezumabgnlm) solution for injection for the treatment of episodic cluster headaches in adults. Emgality offers patients the first FDA-approved drug that reduces the frequency of episodic cluster headache attacks.
Rising Investments in the Development of New Drugs for Migraines to Push Regional Sales
Based on Future Market Insight’s recent analysis, Europe is the second-largest region in revenue share, accounting for nearly 27.3% share of the cluster headache syndrome market. Rapid economic development in Eastern European countries is expected to accelerate this growth further. Moreover, since obtaining CE approval is easier than obtaining FDA approval, production penetration is relatively higher in this region.
According to PubMed, Cluster headache has a lifetime prevalence of 0.2 to 0.3%. Most headaches are more prevalent in women and somewhat less prevalent in children and youth. Some studies indicate that headache prevalence is increasing during the last decades in Europe. Thereby, several governments are making hefty investments in Research and Development to develop fast-acting drugs or even cure chronic headaches.
Galcanezumab is manufactured by Eli Lilly, who provided funding during the trial. In November 2018, the EU approved galcanezumab in Europe for treating migraine. This drug bonds to a protein called calcitonin gene-related peptide (CGRP), which is identified to play a role in cluster headaches.
Increasing Healthcare Spending to Act as a Principal Growth Driver
According to Future Market Insights, the Asia-Pacific market is anticipated to register rapid growth owing to the increase in the aging population and also the increase in the prevalence of cluster headache syndrome in the geriatric population.
This growth can be attributed to the fact that numerous international manufacturers are shifting their production stations in this region due to unmet medical needs and untapped growth prospects.
Besides, the rapid economic development in emerging countries, such as India and China, and increasing healthcare expenditures are projected to support the market development in the region.
Demand for Corticosteroids to remain most prominent
The global cluster headache syndrome market is bifurcated into drug types and regions. Fast-acting drugs are leading in the global cluster headache market based on the drug type segment. Anti-inflammatory medications called corticosteroids, such as prednisone, are fast-acting preventive drugs that can be effective for several people with cluster headaches.
In case of a recent occurrence or the patient have a pattern of brief cluster headaches in patients, doctors prescribe corticosteroids. The fast-acting drugs are also prescribed if the headache has long remission. Though corticosteroids are considered a good option to consume for several days, some serious side effects such as diabetes, hypertension, and cataracts have been detected in a recent study, which makes them inappropriate for long-term consumption.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.2% from 2023 to 2033 |
| Market Value in 2023 | US$ 948.9 million |
| Market Value in 2033 | US$ 1,578.8 million |
| Base Year for Estimation | 2023 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
The market is valued at US$ 948.9 million in 2023.
North America with a 41.2% share will dominate the market.
The market is estimated to exhibit a CAGR of 5.2% through 2033.
Calcium channel blockers to drive the market.
The market held a CAGR of 4.5% from 2017 to 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
5.3.1. Calcium Channel Blockers
5.3.2. Corticosteroids
5.3.3. Sumatriptan
5.3.4. Lithium Carbonate
5.3.5. Ergots
5.3.6. Melatonin
5.3.7. Anti-Seizure Drugs
5.3.8. Local Anesthetics
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
6.1. Introduction
6.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
6.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
6.3.1. North America
6.3.2. Latin America
6.3.3. Western Europe
6.3.4. Eastern Europe
6.3.5. South Asia and Pacific
6.3.6. East Asia
6.3.7. Middle East and Africa
6.4. Market Attractiveness Analysis By Region
7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
7.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
7.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
7.2.1. By Country
7.2.1.1. USA
7.2.1.2. Canada
7.2.2. By Drug Type
7.3. Market Attractiveness Analysis
7.3.1. By Country
7.3.2. By Drug Type
7.4. Key Takeaways
8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. Brazil
8.2.1.2. Mexico
8.2.1.3. Rest of Latin America
8.2.2. By Drug Type
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Type
8.4. Key Takeaways
9. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Germany
9.2.1.2. UK
9.2.1.3. France
9.2.1.4. Spain
9.2.1.5. Italy
9.2.1.6. Rest of Western Europe
9.2.2. By Drug Type
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Type
9.4. Key Takeaways
10. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Poland
10.2.1.2. Russia
10.2.1.3. Czech Republic
10.2.1.4. Romania
10.2.1.5. Rest of Eastern Europe
10.2.2. By Drug Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.4. Key Takeaways
11. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Bangladesh
11.2.1.3. Australia
11.2.1.4. New Zealand
11.2.1.5. Rest of South Asia and Pacific
11.2.2. By Drug Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Drug Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.4. Key Takeaways
13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Drug Type
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Drug Type
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Drug Type
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Drug Type
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Drug Type
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Drug Type
14.6. UK
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Drug Type
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Drug Type
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Drug Type
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Drug Type
14.10. Poland
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Drug Type
14.11. Russia
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Drug Type
14.12. Czech Republic
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Drug Type
14.13. Romania
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Drug Type
14.14. India
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Drug Type
14.15. Bangladesh
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Drug Type
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Drug Type
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Drug Type
14.18. China
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Drug Type
14.19. Japan
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Drug Type
14.20. South Korea
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Drug Type
14.21. GCC Countries
14.21.1. Pricing Analysis
14.21.2. Market Share Analysis, 2022
14.21.2.1. By Drug Type
14.22. South Africa
14.22.1. Pricing Analysis
14.22.2. Market Share Analysis, 2022
14.22.2.1. By Drug Type
14.23. Israel
14.23.1. Pricing Analysis
14.23.2. Market Share Analysis, 2022
14.23.2.1. By Drug Type
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Type
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. AstraZeneca Plc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Autonomic Technologies Inc.
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. ElectroCore Medical LLC
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. GlaxoSmithKline Plc.
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Winston Pharmaceuticals Inc.
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Zosano Pharma
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Eli Lily and Company
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Lundback Seattle BioPharmaceutical
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Novartis AG
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Takeda Pharmaceutical Company Limited
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Cluster Headache Syndrome Market
